by Peter Ciszewski | Apr 12, 2018
National Institutes of Health (NIH) funded researchers completed a genomic analysis, known as the PanCancer Atlas, on a data set of molecular and clinical information from over 10,000 tumors representing 33 types of cancer. “This project is the culmination of more...
by Peter Ciszewski | Apr 12, 2018
Jeff Marrazzo, Co-Founder and CEO of Spark Therapeutics, discusses upcoming milestones in 2018 for his company, including plans to begin a program in Pompe disease. Spark is advancing research programs against cell targets in the retina, liver and central...
by Peter Ciszewski | Apr 11, 2018
Glyn Edwards of Summit Therapeutics discusses his company’s partnerships with the Duchenne muscular dystrophy (DMD) community and with Sarepta Therapeutics. DMD is one of the most common, fatal genetic disorders diagnosed in children around the world. DMD is an...
by Peter Ciszewski | Apr 10, 2018
Kinesin family member 5A (KIF5A), a gene previously linked to two rare neurodegenerative disorders, has been definitively connected to amyotrophic lateral sclerosis (ALS) by an international team from several of the world’s top ALS research labs. The findings identify...
by Peter Ciszewski | Apr 10, 2018
Luca Santarelli, MD of Therachon discusses his company and it’s current research. Therachon’s lead pipeline candidate, TA-46 is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Achondroplasia...
